AKR 203

Drug Profile

AKR 203

Alternative Names: AKR-203

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Akron Molecules
  • Class Analgesics; Anti-inflammatories; Small molecules
  • Mechanism of Action Enzyme inhibitors; Purinergic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 13 Apr 2016 No development reported - Phase-I for Pain in Austria (PO)
  • 16 Oct 2013 Phase-I clinical trials in Pain in Austria (PO) before October 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top